Resection, Percutaneous Radiofrequency Ablation and Transcatheter Arterial Chemoembolization for Small Hepatocellular Carcinoma:a Prospective Randomized Controlled Trial

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000617

Enrollment

Unknown

Registered

2009-12-18

Start date

2010-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

A:resection

B:percutaneous radiofrequency ablation (PRFA)

C:transcatheter arterial chemoembolization (TACE)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosis is "hepatocellular carcinoma(HCC)"; (2) Single nodule<=3cm with cirrhosis but without macrovascular tumor embolus or extrahepatic metastasis; (3) Liver function is Child-Pugh A or B; (4) Patients that do not receive any other anti-tumor therapy previously.

Exclusion criteria

Exclusion criteria: (1) Patients that refuse to participat in the trial; (2) Patients that can not be followed-up regularly; (3) Patients that have server damage of the heart, lung or kidney function.

Design outcomes

Primary

Measure	Time frame
1-, 3-, 5-year over-all survival;	—

Secondary

Measure	Time frame
1-, 3-, 5-year recurrent and metastasis rate;	—

Countries

China

Contacts

Public ContactJanjun Yan

li_5hao@163.com+86 021 81875503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026